Lucky No 5? Pharmacyclics collects $50mn for fifth patient in ibrutinib trial
This article was originally published in Scrip
Five, or maybe 50, must be Pharmacyclics' lucky number: the Sunnyvale, California-based company collected a $50 million milestone payment from Janssen Biotech when the fifth patient was enrolled in the Phase III RESONATE clinical trial evaluating the partners' ibrutinib (PCI-32765) versus GlaxoSmithKline's Arzerra (ofatumumab) in patients with relapsed or refractory lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL).
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.